T
he following recommended practices for pre operative patient skin antisepsis were devel oped by the AORN Recommended Practices Committee and have been approved by the AORN Board of Directors. They were presented as proposed recommendations for comments by members and others. They are effective January 1, 2008. These rec ommended practices are intended as achievable rec ommendations representing what is believed to be an optimal level of practice. Policies and procedures will reflect variations in practice settings and/or clin ical situations that determine the degree to which the recommended practices can be implemented. AORN recognizes the various settings in which periopera tive nurses practice. These recommended practices are intended as guidelines adaptable to various prac tice settings. These practice settings include tradi tional operating rooms, ambulatory surgery centers, physician's offices, cardiac catheterization laborato ries, endoscopy suites, radiology departments, and all other areas where surgery may be performed. The reader is referred to the Perioperative Nursing Data Set (PNDS) for explanation of perioperative nursing diagnoses, interventions, and outcomes. 1 
Purpose
These recommended practices provide a guideline for achieving skin preparation of the surgical site. The goal of preoperative preparation of the patient's skin is to reduce the risk of postoperative surgical site infection by removing soil and transient microor ganisms from the skin; reduce the resident microbial count to subpathogenic levels in a short period of time and with the least amount of tissue irritation; and inhibit rapid, rebound growth of microorgan isms. The following recommended practices are con sidered established guidelines for perioperative practice.
Recommendation I
Patients undergoing open Class I surgical procedures below the chin should have two preoperative showers with chlorhexidine gluconate (CHG) before surgery, when appropriate. 2 The act of washing and rinsing removes micro organisms from the skin. Some organisms may be dif ficult or impossible to kill with the application of CHG alone.
Staphylococcus aureus is the most common organ ism causing surgical site infections. 2, 3 In 2003, 64.4% of health careassociated Staphylococcus aureus infections were from methicillinresistant Staphylococcus aureus (MRSA). 4, 5 Many surgical site infec tions result from colonization of the surgical site with the patient's own flora; and colonization with Staphylococcus aureus is a known risk factor for surgical site infection. 2, 6, 7 Clinical trials support the use of pre operative antiseptic showers to reduce the number of microorganisms on the skin, including Staphylococcus aureus. 811 In 1999, the Centers for Disease Control and Prevention recommend requiring patients to "shower or bathe with an antiseptic agent at least the night before the operative day" (Category IB). Unless contraindicated, patients should be instructed or assisted to perform two preoper ative baths or showers with CHG before sur gery to reduce the number of microorganisms on the skin and reduce the risk of subsequent contamination of the surgical wound.
I.a.1. Four percent CHG is more effective than povidoneiodine or soap, and more than one shower is necessary to achieve maxi mum antiseptic effectiveness. 8, 9 One pre operative shower with 4% CHG was found to be twice as effective in reducing skin bacterial flora as showering with nonmed icated soap. 3 Two showers with 4% CHG were found to result in lower microbial counts than showers with bar soap, medi cated soap, or povidoneiodine. 8, 9 This greater reduction in microbial counts per sisted for more than 11 hours. 8 One ran domized clinical trial found two consecu tive showers or baths with 4% CHG resulted in lower surgical site infection rates than bar soap (ie, 9% versus 12.8%). 9 Showering three times with 4% CHG was found to reduce skin flora 20fold preoper atively and to lower bacterial counts of the incision taken at the end of the procedure. 10 Researchers studied the effects of preop erative showering with 4% CHG and povi doneiodine on skin microbial counts of patients colonized with Staphylococcus aureus. Two consecutive showers with 4% CHG the evening before surgery reduced microbial counts in the subclavian and groin areas; however, povidoneiodine had little effect on colonization of the groin. Showering both the evening before and the morning of surgery with 4% CHG reduced the bacterial count further at both sites; povidoneiodine provided inconsistent results; and showering with lotion soap increased the colony counts in both the subclavian site and groin. Rinsing the skin removes residual CHG that may cause skin irritation. After use, towels contain microorganisms that can grow in the presence of moisture. Using a fresh towel after each shower and donning clean clothing minimizes the risk of reintro ducing microorganisms to clean skin.
I.b.
Chlorhexidine gluconate preparation products used for preoperative showers should be US Food and Drug Administration (FDA)approved or cleared for use as a general cleansing agent. The FDA determines the appropriate uses for all approved or cleared products. 16, 17 I.c.
Patients undergoing surgery on the head should be instructed or assisted to perform two preop erative shampoos with 4% CHG before surgery to reduce the number of microorganisms and subsequent contamination of the surgical site. Two shampoos with 4% CHG reduce the emergence of resident skin flora and contamina tion of the surgical wound. 18 Researchers found that patients receiving two 4% CHGshampoos and an intraoperative skin prep with 4% CHG had fewer bacteria on the scalp, both preopera tively and postoperatively, and had significantly fewer positive postoperative scalp cultures than patients receiving either shampoos with povidoneiodine or no shampoos. 18 Conditioners and other hair care products should not be used after performing preopera tive shampoos because a chemical reaction between CHG and the hair care product may impede the antiseptic effectiveness of the CHG. 19 I.c.1.
Hair spray and other alcoholbased hair products should not be used during head and neck surgery. Alcoholbased hair products are flamma ble and should not be left on the hair during head and neck surgery because they pose a fire hazard. 19, 20 I.d.
Caution should be exercised to avoid CHG con tact with the eyes, the inside of the ears, the meninges, or other mucous membranes. Chlorhexidine gluconate is irritating to the eye and can cause corneal damage. 19 Exposure of CHG to the inner ear can result in permanent deafness. 13, 19, 22 I.d.1.
If CHG solution gets into the eye, immedi ately rinse the area with copious amounts of running water for at least 15 minutes and seek medical attention.
Chlorhexidine gluconate should not be used on the head if the patient's tympanic mem brane is not intact.
I.e. Chlorhexidine gluconate should not be used on patients for whom it is contraindicated, includ ing patients with a known hypersensitivity to CHG or any other ingredient in the product. 19, 22 Isolated incidents of hypersensitivity to CHG have been reported. Relatively minor symptoms upon exposure have preceded more serious reactions in some patients. 19 
Recommendation II
Preoperative skin antiseptic agents that have been FDAapproved or -cleared and approved by the health care organization's infection control personnel should be used for all preoperative skin preparation.
The FDA determines the appropriate uses for products which the agency has approved or cleared. 16 II.a. Current research, recommendations from the Association for Professionals in Infection Con trol and Epidemiology, FDA information, manu facturers' literature, and material safety data sheets (MSDSs) should be consulted when selecting antiseptic agents for skin preparation within health care organizations.
Decisions about which skin antiseptics should be used in the practice setting are com plex. A variety of products may be necessary to meet the needs of various patient populations. Input from an infection control professional knowledgeable about antiseptics is helpful when reviewing the current research and docu mentation provided by manufacturers.
II.b. The preoperative skin antiseptic agent should:
significantly reduce microorganisms on intact skin, RP: Patient Skin Antisepsis contain a nonirritating antimicrobial preparation, be broad spectrum, be fast acting, and have a persistent effect. 17 An antimicrobial ingredient is intended to kill microorganisms. A characteristic of certain antiseptic agents that sets them apart from plain soap is their ability to bind with the stratum corneum of the skin, resulting in persistent chemical activity. Alcohols provide the most rapid and greatest reduction in initial microbial counts on skin, but have no persistent activity. 8 Persistent antimicrobial activity (ie, measured in hours) helps decrease rebound mi crobial growth after skin preparation. Table 1 provides a summary of the characteristics of commonly used skin antiseptic agents.
II.c. Products selected for preoperative skin prepara tion should meet FDA requirements, as outlined in the Tentative Final Monograph (TFM) for HealthCare Antiseptic Drug Products, or be the subject of a "New Drug Approval" or an "Abbre viated New Drug Approval" process. 16, 17, 24 The FDA requires products for preoperative skin preparation to be fast acting (ie, a twolog bacterial reduction on the abdomen and threelog reduction on the groin within 10 minutes), and persistent (ie, no return to baseline flora count at six hours post application). 16 II.c.1. Persistence of the antimicrobial effect sup presses the regrowth of residual skin flora not removed by preoperative prepping, as well as suppressing transient microorgan isms contacting the prepped site.
II.c.2.
Infection control professionals and commit tees should review the data provided by manufacturers to ensure that surgical anti sepsis agents comply with current FDA test ing and labeling criteria. The testing should be performed at an independent testing lab oratory complying with current FDA r e q u i r e m e n t s a n d s u b j e c t t o F D A inspection. The laboratory should employ either ASTM International (formerly known as the American Society for Testing and Materials) standard methods, or methods specifically approved by the FDA for use in conjunction with a particular New Drug Application subject product.
II.c.3.
Consult scientific data when selecting new products for use.
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Recommendation III
The antiseptic agent used should be selected based on the patient assessment.
The patient should be assessed for considerations affecting skin preparation.
III.a. The patient should be assessed for allergy or sensitivity to skin preparation agents.
III.a.1. Povidoneiodine can cause contact dermati tis or irritant reactions and does not indi cate an allergy to iodine. Anaphylaxis to povidoneiodine is extremely rare and has not been proven to be from the iodine. 26 There is no correlation between reactions to povidoneiodine and allergy to seafood or contrast media. III.c. The surgical site should be identified before skin preparation. The surgical site should be confirmed before initiating the skin prep. This verification mini mizes the risk of prepping the wrong area, which could contribute to wrongsite surgery.
III.c.1.
Verification should be done in advance of the "time out" period, which occurs imme diately before the surgeon makes the incision.
III.d. The marker used to make the surgical site mark should not facilitate microbial growth, and provide a mark that remains visible after the surgical prep.
25,37
Marking the skin with an alcoholbased sur gical site marker before skin preparation does not increase the amount of microorganisms on the skin. 38 Waterbased skin markers may wash RP: Patient Skin Antisepsis III.e. The patient's skin condition should be assessed for the presence of lesions or other tissue conditions at the surgical site before skin prep aration begins.
Unintentional removal of lesions (eg, nevi) traumatizes the skin at the surgical site and pro vides an opportunity for wound colonization by microorganisms.
III.e.1.
The presence of excessive hair that may interfere with the surgical procedure should be identified.
III.f. The antiseptic product used for an individual patient should be selected based on patient allergies; a patient's report of significant skin irritation from specific antiseptic agents; RP: Patient Skin Antisepsis contraindications to specific antiseptic agents; the surgical site to be prepped; the presence of organic matter, including blood; neonatal status; large, open wounds; a review of written manufacturer's informa tion; and surgeon preference. Antiseptic agents used on the skin of patients with known hypersensitivity reactions (ie, aller gies) may cause adverse outcomes (eg, blisters, rashes). Some antiseptic agents are affected by organic matter and/or saline and are rendered less effective (see Table 1 ). Some antiseptic agents may be absorbed by the skin or mucous membranes and become neurotoxic or ototoxic. Certain antiseptic agents are believed to be potentially harmful to neonates. Products made specifically for use on mucous membranes should be used following manufacturers' recommendations.
Recommendation IV
Hair at the surgical site should be left in place (ie, not removed) whenever possible.
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Research studies have found that preoperative shaving of the surgical site increases the risk of surgical site infection 4042 and results in higher surgical site infection rates than using a depilatory cream or clipping. 42 Hair has successfully been left in place for neurosurgery without increasing the risk of surgical site infection. 43, 44 IV.a. The patient should be instructed not to shave or use a depilatory on the surgical site before surgery.
Removing hair at the surgical site abrades the skin surface and enhances microbial growth. Shaving has been found to increase the risk of surgical site infection. 4042 Depilatory creams may cause skin reactions in some individuals, which could result in cancellation of surgery. Alternatives to hair removal for head and neck surgery include:
• braiding hair instead of shaving; and • using a nonflammable gel to keep the hair away from the incision.
If the presence of hair will interfere with the surgical procedure and removal is in the best interest of the patient, the following precautions should be taken:
• Hair removal should be performed the day of surgery, in a location outside of the operating or procedure room.
• Only hair interfering with the surgical procedure should be removed.
• Hair should be clipped using a singleuse electric or batteryoperated clipper, or a clipper with a reusable head that can be disinfected between patients. Clipping hair the morning of surgery has resulted in fewer surgical site infections than shaving or clipping the day before sur gery. 45 Limiting the amount of clipping min imizes the risk of microscopic nicks. Clip ping the hair outside of the operating room minimizes the dispersal of loose hair and the potential for contamination of the sterile field and surgical wound. During use, the clipper handle is contaminated with the patient's skin flora. The clipper head may become contaminated with microscopic blood or body fluids; therefore, decontami nation for bloodborne pathogens is neces sary to prevent transmission.
IV.b.3.
Depilatories may be used for hair removal if skin testing has been performed without tis sue irritation. Depilatories may be used when hair is to be removed from the operative site. The use of depilatories, however, does increase the risk of hypersensitivity reactions. The writ ten manufacturers' instructions regarding skin testing and the use of chemical depila tories should be followed.
Recommendation V
The skin around the surgical site should be free of soil, debris, exudates, and transient microorganisms to minimize contamination of the surgical wound before application of the antiseptic skin preparation.
The efficacy of antiseptic agents is dependent on the cleanliness of the skin. Removal of superficial soil, debris, and transient microbes before applying antisep tic agents reduces the risk of wound contamination by decreasing the organic debris on the skin.
• No skin antiseptic alone is effective in killing spores (eg, clostridium).
• Some anatomic areas contain more debris than others (eg, umbilicus, under fingernails, under foreskin). Cleaning these areas separately from the surgical prep prevents distribution of micro organisms from these areas to the surgical site.
• Cleaning the foot before antiseptic skin prepara tion for surgery was found more effective in reducing bacterial counts between the toes than application of the antiseptic alone. To remove facial cosmetics, the face should be gently cleansed with a nonirritating agent. Initial cleansing of the eyes, before appli cation of the antiseptic agent, is not neces sary because tears naturally rinse most con taminants from the eye.
V.c. For abdominal surgery, the umbilicus should be cleaned before the antiseptic skin preparation. The organic and inorganic material in the umbilicus is a contaminant and cannot be ade quately disinfected.
V.c.1.
To soften umbilical detritus, antiseptic solu tion may be instilled into the umbilicus before cleaning. RP: Patient Skin Antisepsis
Cotton applicators may be used to remove the detritus.
V.d. Jewelry (eg, body piercing ornaments) at the surgical site should be removed before cleans ing the skin. Jewelry harbors microorganisms and traps these organisms in adjacent skin. Wearing of rings has been associated with up to a 10fold increase in median skin microorganism count (ie, bioload). 47 Removal of jewelry before skin cleansing provides an opportunity to more effectively remove these microorganisms from the area that will be prepped.
Jewelry should be removed to reduce the risk of injury related to • positioning, 48 and • proximity to the incision site or active electrosurgical unit (ESU) electrode. 49 V.e. An intestinal or urinary stoma within the surgi cal field should be cleansed gently and sepa rately from the rest of the prepped area. Some antiseptics are ineffective in the pres ence of organic material. Cleansing of the stoma removes mucin and organic material that impedes the effective ness of the antiseptic agent.
V.f. Surgical fields that include the penis require the foreskin (ie, prepuce), if present, to be retracted before the glans is gently cleansed. Organic material (ie, smegma) and micro organisms accumulate under the foreskin.
V.f.1.
After cleaning, the foreskin should be pulled back over the glans to prevent circu latory compromise.
V.g. For surgery on the hand or wrist, the patient's nails should be short and natural without artifi cial nail surfaces (eg, extensions, overlays, acrylic, silk wraps, enhancements) in the prepped area. The subungual region harbors the majority of microorganisms found on the hand. The variety and amount of potentially pathogenic bacteria cultured from fingertips of persons wearing arti ficial nails is greater than from those with natu ral nails, both before and after handwashing. There is insufficient evidence to determine whether fresh or chipped nail polish in the sur gical field increases the risk of surgical site infection. 53 There is, however, a theoretical risk of chipped nail polish fragments entering the wound.
V.h. Cleansing traumatic orthopedic injuries with exposed bone may be facilitated by pulse lavage, highpressure parallel waterjet, or brushsuction irrigation. In a randomized clinical trial, lowpressure pulse lavage decreased wound contamination by 86.9% and highpressure parallel waterjet decreased contamination by 90.8%. 54 In a labo ratory study, highpressure lavage removed less inorganic contaminants and caused more tissue damage than a brushsuction method.
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When irrigating traumatic wounds: sterile 0.9% saline solution should be used for the irrigation; caution should be exercised to avoid aerosol ization of wound contaminants onto the sterile field during irrigation; and the use of a pulse lavage protective shield may be beneficial.
Recommendation VI
Protective measures should be implemented to prevent skin and tissue injury due to prolonged contact with skin prep agents.
Chemical burns and skin irritations are more likely when antiseptic solutions are not allowed to dry and remain in contact with the skin for prolonged periods of time.
22,31,56
The iodine in povidoneiodine prep solutions remains free until it has dried and can chemically irri tate the skin. When the skin is occluded, the solution is unable to dry, the chemical contact is sustained, and the skin is macerated. 
Recommendation VII
The antiseptic agent should be applied to the skin over the surgical site and surrounding area in a manner to minimize contamination, preserve skin integrity, and prevent tissue damage.
VII.a. Nonscrubbed personnel should apply the skin antiseptic. The risk of contamination to sterile gown and gloves is high, in most circumstances, when scrubbed personnel perform the prep. VII.b. Hand hygiene should be performed before initi ating the surgical prep. 57, 58 Hand hygiene pre vents contamination of the prepped area in the event of a glove failure.
VII.c. Antiseptic agents used for skin preparation should be applied using sterile supplies. There is insufficient evidence to determine if using only clean supplies is a safe practice. In one study, using a combination povidoneiodine scrub and paint, researchers found that using clean prep kits with reusable sponge sticks for the paint, assembled in a central sterilizing area, did not result in higher microbial counts on the skin than when similar trays were sterilized first.
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VII.c.1. Sterile gloves should be worn unless the antiseptic prep applicator is of sufficient length to prevent the antiseptic and patient's skin from contact with the nonster ile glove.
VII.c.2. Any supplies touching the prepped area after the prep has been completed should be VII.e. Application of the skin antiseptic should prog ress from the incision site to the periphery of the surgical site.
In most surgical procedures, the incision site is in close proximity to anatomic areas with high microbial counts (eg, laparotomy incision/ umbilicus/groin; neck/mouth/nares; ankle/toes; shoulder/axilla; hand/fingernails). Progressing from the incision site to the periphery prevents reintroducing microorganisms from these areas into the incision site.
VII.e.1. The prep sponge or applicator should be used for a single application and discarded.
VII.e.2. Subsequent applications should be applied with a fresh sponge or applicator to prevent contamination of the incision site.
VII.e.3. When using a commercially available appli cator, refer to the manufacturer's instruc tions to ensure uniform distribution of the antiseptic.
VII.f. Special consideration on skin prep implementa tion is necessary when the incision site is more highly contaminated than the surrounding skin.
VII.f.1. If a highly contaminated area is part of the procedure, the area with a lower bacterial count is prepped first, followed by the area of higher contamination, as opposed to working from the incision site toward the periphery. VII.j. Adhesive incision drapes may be used to mini mize the gaping and shifting of surgical drapes and to contain residual microorganisms on the skin. Adhesive incision drapes may be advanta geous in sealing the surgical field; however, the utility of the iodineimpregnation of these drapes has not been demonstrated. 65 One ran domized clinical trial investigating the utility of these drapes after povidoneiodine prep reported no reduction in surgical site infection risk when using iodineimpregnated incision drapes.
66
Recommendation VIII
If a flammable prep agent is used, additional precautions should be taken to minimize the risk of a surgical fire and patient burn injury.
Using flammable skin prep agents in the operating room or procedural area poses a serious risk of fire because of the common use of ignition and heat sources (eg, electrosurgery, lasers, drills, fiberoptic cables). Special precautions have been developed by the National Fire Protection Association (NFPA), and have been incorporated in the National Patient Safety Goals by the Joint Commission. 63, 67 VIII.a. Perioperative personnel should be familiar with the flammability characteristics of all prep agents stored or used in the patient care area. Fires have resulted when personnel did not know or remember that a prep agent was flam mable and used a heat source during the procedure. 68 VIII.b. When flammable prep agents are used, they should be packaged in small quantities appro priate for a single application or be prepackaged in a unit dose. 63, 67 Packaging in small quantities may minimize the risk of soaking materials adjacent to the prepped area and limits the amount left over for disposal.
VIII.c. The prep agent should not contact fabric or be allowed to pool on or under body parts (eg, umbilicus, groin). Solution in contact with fabric may not dry adequately. Pooled prep agents require longer periods of time for evaporation. VIII.d. If pooling occurs, the excess solution should be wicked away. Any solutionsoaked materials should be removed from the procedure room before draping or using electrosurgery, laser, or other heat source. 63, 64, 67 Wicking solution away from pooled areas allows the remaining solution to dry adequately. Solutionsoaked materials are easily ignitable, and removal from the operating room mini mizes the risk of fire.
VIII.e. The prep agent should be allowed to dry and vapors to dissipate before application of an incise drape or surgical drape, or use of electro surgery, laser, or other heat source.
6264
The prep agent remains flammable until com pletely dry. Vapors occurring during evapora tion are also flammable. Trapping of solution or vapors under drapes increases the risk of fire or burn injury.
VIII.f. The use of a flammable prep agent should be discussed during the "time out" period used to verify the surgical procedure and site. Active communication about the use of flam mable prep agents alerts all personnel to the inherent risks and verifies that appropriate pre cautions have been taken. At times, the person operating the heat (ie, ignition) source may be unaware that a flammable prep agent was used. A c t i v e c o m m u n i c a t i o n p r e v e n t s t h i s misunderstanding.
VIII.f.1. Active communication between the surgical team members should include that • a flammable prep agent was used;
• the application site was dry before draping;
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• pooling of the prep solution did not occur or has been corrected; and • any materials soaked with the prepping agent have been removed from the proce dure room. 63, 67 VIII.g. Disposal of unused flammable prep agents must be handled in a manner to decrease the risk of fire and in accordance with federal, state, and local regulations. Disposal of residual flammable prep agents is regulated by the Environmental Protection Agency. 69 Fires can occur when these agents are discarded in nonhazardous trash. Incineration or autoclaving of biohazardous waste can rap idly ignite flammable prep agents.
VIII.g.1. Residual flammable prep agents may be safely discarded in a chemical hazardous waste receptacle outside of the operating or procedure room or immersed in water in a soiled utility room to render the agents nonhazardous.
VIII.h. Flammable skin preparation agents should not be heated.
Heating flammable preparation agents poses a serious risk of fire. When the temperature of these agents increases, they become more unsta ble and may ignite easily.
Recommendation IX
Manufacturers' written recommendations and MSDSs for handling, storing, and heating of all skin preparation agents should be readily available, reviewed, and followed.
Testing antimicrobial agents is a complex process and not practical in the patient care setting. Data from cur rent research, manufacturers' literature, and the FDA provide direction for storage, safe use, and product efficacy.
IX.a. Skin antiseptic agents should be stored in their original containers; these containers should not be refilled. Prolonged use of a multiuse container, trans ferring solutions to secondary containers, and refilling containers of povidoneiodine has resulted in contamination of the antiseptic with Pseudomonas aeruginosa. 7074 These microorgan isms can survive more than one year in povi doneiodine 71 ; and contaminated povidone iodine has resulted in transmission of the contaminating organism and subsequent infec tions. 71, 72, 7476 Use of singledose containers elimi nates this risk.
IX.b. If the skin preparation solution is poured into a secondary container, it should be labeled and the label verified before use of the prep agent. A label placed on the secondary container communicates to anyone using the agent the contents of the container. A patient death resulted when a skin preparation agent was erroneously mistaken for another drug and injected. 77 Health care accreditation agencies require labeling to identify the skin preparation name and strength. 81 Manufacturers may have a time limit that an antiseptic agent may be warmed slightly, after which it should be discarded.
IX.d. Skin preparation agents should never be warmed in a microwave oven or autoclave. The temperature of the skin preparation agent is uncontrolled when heated in a micro wave or autoclave, and temperature extremes may result in a patient injury.
IX.e. Material safety data sheets for all antiseptic agents and other chemicals used must be avail able in the practice area.
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Material safety data sheets provide informa tion about the flammability of skin antiseptic agents and the maximum safe storage tempera ture. The Occupational Safety and Health Administration (OSHA) requires that MSDSs be available for all chemicals used in the practice setting. These documents outline the hazards related to the chemicals and appropriate action to be taken in the event of an exposure (eg, splash to the eyes). 22,56 Some manufacturers recommend that specific preparation agents be left on the skin and allowed to wear off naturally.
X.a.2.
As soon as feasible, the patient should be rolled to the side and posterior skin sur faces examined to identify any residual antiseptic that should be removed. A thorough evaluation of the patient's skin may need to be postponed until after the patient is transferred to the postopera tive area.
Recommendation XI Competency
Personnel should receive initial education, training, and competency validation on skin preparation agent selection, application procedures, and patient assessments.
Initial competency validation, in addition to the annual review and evaluation of individual compe tency skills, should be performed to maintain profi ciency in application of knowledge and use of critical thinking concerning performance of skin preparation.
XI.a. Personnel who could be potentially exposed to antiseptic preparation agents must be made aware of the exposure risk associated with these chemicals. 
Recommendation XIII Policies and Procedures
Policies and procedures on the skin preparation of patients should be written, reviewed annually, and readily available within the practice setting.
Policies and procedures assist in the development of patient safety, and quality assessment and improvement activities. Policies and procedures establish authority, responsibility, and accountability and serve as opera tional guidelines. Policies and procedures establish guidelines for performance improvement activities to be used when monitoring and evaluating skin preparation in the operating room.
XIII.a. Policies about preoperative skin preparation should be developed in collaboration with sur geons and an infection control professional.
XIII.a.1. Policies should include, but not be limited to, • patient education or assistance in per forming two CHGshowers; • appropriate restrictions on and alterna tives to hair removal; • removal of jewelry at the surgical site; • assessments to be performed before skin preparation; • approved skin antiseptic agents; • if flammable skin preparation agents are permitted or not; • precautions to be taken if flammable skin preparation agents are used; • removal of preparation agents and evalua tion of the skin condition at the end of the procedure; • documentation; • storage of flammable skin preparation agents; • maintenance of MSDS sheets; and • reporting adverse events.
XIII.b. An introduction and review of policies and pro cedures should be included in the initial orien tation and ongoing education of health care personnel.
Review of policies and procedures assist health care professionals in the development of knowledge, skills, and attitudes that affect patient outcomes.
Recommendation XIV Quality
A quality management program should be in place to evaluate skin preparation procedures and identify and respond to opportunities for improvement.
A fundamental precept of AORN is that it is the responsibility of professional perioperative registered nurses to ensure safe, highquality nursing care to patients undergoing operative and invasive procedures.
XIV.a. A quality management program should be in place to evaluate skin preparation procedures and to identify and respond to opportunities for improvement. "Surgery patients with appropriate hair removal" is a Surgical Care Improvement Project and National Hospital Quality Measures evi dencebased practice indicator used by the Cen ters for Medicare and Medicaid Services and the Joint Commission. 8486 The abstraction criterion indicating compliance is: "Surgical patients with surgical site hair removal by clippers or depilatory or no surgical site hair removal." 84 Public reporting of the percent of compliance with this indicator is required for Medicare or Medicaid reimbursement. 86, 87 XIV.b. Adverse reactions to skin antiseptic agents should be reported in the health care or gani zation's adverse event reporting system and reviewed for potential opportunities for improvement.
XIV.b.1. Surgical fires resulting from skin prepara tion agents should be reported and investi gated as serious adverse events through a root cause analysis and corrective action taken to prevent recurrence.
XIV.b.2. Near misses should be investigated and cor rective action taken to prevent serious adverse events.
Glossary
Antisepsis: The prevention of sepsis by preventing or inhibiting the growth of resident and transient microbes.
Antiseptic: A product with antimicrobial activity that formerly may have been referred to as an antimicrobial agent.
Antiseptic agent: Antimicrobial substance applied to the skin to reduce the log number of microbial flora. Examples include alcohols, chlorhexidine gluconate, chlorine, hexachlorophene, iodine, parachloroxylenol, quaternary ammonium compounds, and triclosan.
Denature: To alter the chemical structure of a pro tein so that biological activity is diminished or elimi nated. Made unnatural or changed from the normal in any of a substance's characteristics. RP: Patient Skin Antisepsis Detritus: Accumulated debris resulting from the wearing away or deterioration of tissue or other depos ited material. Any brokendown material.
Flammable: Capable of being easily ignited and burning rapidly.
Gluteal cleft: Cleft of the buttocks. Iodism: Poisoning by iodine, manifested by severe rhinitis, frontal headache, emaciation, weakness, and skin eruptions. Caused by the administration of iodine or one of the iodides.
Log reduction: The logarithmic death progression of microorganisms after exposure to a sterilant or antisep tic agent. The reduction difference between average surviving microbes for control and test carriers used as an efficacy parameter.
Neurotoxic: Poisonous or destructive to nerves, nerve tissue, or nervous system.
Ototoxic: Having a toxic or injurious effect on the ear, especially the nerve supply, affecting hearing and balance.
Oxidation: The combination of a substance with oxygen, altering cell biologic activity.
Subungual: Under the nail (eg, fingernail). Toxicity: The degree to which a substance can harm humans or animals.
